期刊文献+

褪黑素联合顺铂、甲氨蝶呤对骨肉瘤SaOS-2细胞增殖的影响 被引量:2

Effects of Melatonin Combined with Cis-platinum or Methotrexate on the Proliferation of Osteosarcoma Cell Line SaOS-2
下载PDF
导出
摘要 目的探讨褪黑素(Mel)联合顺铂(DDP)、甲氨蝶呤(MTX)对骨肉瘤细胞系Sa OS-2增殖的影响,以及Mel与DDP、MTX是否具有协同抗肿瘤作用。方法 Mel、DDP、MTX、Mel+DDP、Mel+MTX作用于Sa OS-2细胞后,CCK-8法检测药物对细胞活性的影响,应用Compusyn软件分析药物的合并效应,流式细胞术分析细胞周期分布及细胞凋亡率。结果与对照组相比,Mel、DDP、MTX单独均能显著降低Sa OS-2细胞活性(P均<0.05),且呈剂量-效应关系。与单用DDP或MTX相比,Mel与DDP或MTX联合应用能显著降低Sa OS-2细胞的活性(P均<0.05)。1 mmol/L的Mel与6.67、16.67、33.33、66.66μmol/L的DDP合用时,联合用药指数(CI)分别为1.18、1.21、1.09、0.84,与0.1、0.5、1、2、4 mmol/L MTX合用后,CI分别为0.88、0.88、0.83、0.78、0.81。与对照组相比,Mel组与Mel+MTX组的G1期细胞比例显著增多(P均<0.05),S期细胞比例显著减少(P均<0.05);MTX组的S期细胞比例显著增多(P均<0.05)。药物作用组的细胞凋亡率均显著高于对照组(P均<0.05),联合用药组的细胞凋亡率显著高于单药组(P均<0.05)。结论 Mel在体外能抑制Sa OS-2细胞的活性,阻滞细胞周期于G1期,诱导凋亡,发挥抗肿瘤效应,与较低浓度DDP呈拮抗效应,而与MTX、较高浓度DDP联合应用时呈协同抗肿瘤效应。 Objective To evaluate the effects of melatonin( Mel) combined with cis-platinum( DDP)or methotrexate( MTX) on the proliferation of osteosarcoma cell line Sa OS-2,and to explore whether Mel combined with DDP or MTX could play a synergistic antitumor effect. Methods Sa OS-2 was treated with Mel alone or Mel combined with DDP or MTX. Cell counting kit-8 assay was used to measure the cell activities. Combination index( CI) value was used to evaluate the combined effects: CI 1 indicating synergetic effect,CI = 1 additive,and CI 1 antagonistic. Flow cytometry was used to analyze cell cycle distribution and cell apoptosis. Results After treated with Mel( 0. 5,1,2,4,5 mmol / L), DDP( 6. 67,16. 67,33. 33,66. 66μmol / L) or MTX( 0. 1,0. 5,1,2,4 mmol / L) alone,Sa OS-2 cell activities decreased in a dose-dependent manner( all P 〈0. 05). The activities of Sa OS-2 cell treated with both Mel( 1 mmol / L) and DDP or MTX were significantly lower than that of DDP or MTX alone( all P 〈0. 05). CI values of cells exposed to 1 mmol / L Mel plus 6. 67,16. 67,33. 33,and 66. 66 μmol / L DDP were 1. 18,1. 21,1. 09,and 0. 84,respectively,and CI values of cells exposed to 1 mmol / L Mel plus 0. 1,0. 5,1,2,and 4 mmol / L MTX were 0. 88,0. 88,0. 83,0. 78,and 0. 81,respectively. The G1-stage cells were increased and the S-stage cells were reduced when the cells were treated with Mel( 1 mmol / L) alone or combined with MTX( 0. 5 mmol / L)( P 〈0. 05). The Sstage cells were increased when the cells treated with MTX( 0. 5 mmol / L)( P 〈0. 05). The apoptotic cells were increased when they treated with Mel( 1 mmol / L) alone or combined with DDP( 16. 67 μmol / L) or MTX( 0. 5 mmol /L)( P 〈0. 05). When the cells were treated with Mel combined with DDP or MTX,the apoptotic cells were more than that of DDP or Mel alone( P 〈0. 05). Conclusions Mel can inhibit Sa OS-2 cells activity,block the cell cycle at G1-stage,and induce apoptosis. Mel has an antagonistic effect with lower concentration of DDP but a synergistic effect with MTX or higher concentration of DDP.
出处 《中国医学科学院学报》 CAS CSCD 北大核心 2015年第2期215-220,共6页 Acta Academiae Medicinae Sinicae
关键词 骨肉瘤 褪黑素 顺铂 甲氨蝶呤 osteosarcoma melatonin cis-platinum methotrexate
  • 相关文献

参考文献22

  • 1Berk L, Berkey B, Rich T, et al. Randomized phase II tri- al of high-dose melatonin and radiation therapy for RPA class 2 patients with brain metastases (RTOG 0119) [ J ]. Int J Radiat Oncol Biol Phys, 2007, 68(3) :852-857.
  • 2Di Bella G, Mascia F, Ricchi A, et al. Evaluation of the safety and efficacy of the first-hne treatment with somatostatin combined with melatonin, retinoids, vitamin D3, and low doses of cyclophosphamide in 20 cases of breast cancer: a preliminary report [ J ]. Neuro Endocrinol Lett, 2013, 34 (7) :660-668.
  • 3Schernhammer ES, Giobbie-Hurder A, Gantman K, et al. A randomized controlled trial of oral melatonin supplementa- tion and breast cancer biomarkers [ J ]. Cancer Causes Con- trol, 2012, 23(4):609-616.
  • 4Tan DX, Poeggeler B, Reiter lad, et al. The pineal hor- mone melatonin inhibits DNA-adduet formation induced by the chemical carcinogen safrole in vivo [J]. Cancer Lett, 1993, 70(1-2) :65-71.
  • 5Espino J, Bejarano I, Paredes SD, et al. Protective effect of melatonin against human leukocyte apoptosis induced by intra- cellular calcium overload: relation with its antioxidant actions [J]. J Pineal Res, 2011, 51(2):195-206.
  • 6Yu Q, Miller SC, Osmond DG. Melatonin inhibits apoptosis during early B-cell development in mouse bone marrow [ J]. J Pineal Res, 2000, 29(2) :86-93.
  • 7Liu L, Xu Y, Reiter RJ. Melatonin inhibits the proliferation of human osteosarcoma cell line MG- 63 [ J ]. Bone, 2013, 55(2) :432-438.
  • 8Chou TC. Drug combination studies and their synergy quantifi- cation using the Chou-Talalay Method [ J ]. Cancer Res, 2010, 70(2) :440-446.
  • 9Garcia-Santos G, Antolin I, Herrera F, et al. Melatonin in- duces apoptosis in human neuroblastoma cancer cells [ J ]. J Pineal Res, 2006, 41(2) :130-135.
  • 10Garcfa-Santos G, Martin V, Rodrfguez-Blanco J, et al. Fas/ Fas ligand regulation mediates cell death in human Ewing' s sarcoma cells treated with melatonin [J]. Br J Cancer, 2012, 106(7) :1288-1296.

二级参考文献11

  • 1Cardinali D P. Melatonin, Physiology and clinical, applications[J]. Vertex,2007,18 (74) : 288-293.
  • 2Ekm ekcioglu C. Melaton in receptors in humans: biological role and clinical relevance[J]. Biomed Pharmacother, 2006,60 (3) : 97-108.
  • 3Duboeovich M L,Mark owska M. Functional MT1 and MT2 melatonin re- ceptors in mammals[J]. Endocrine,2005,27(2) : 101- 110.
  • 4Toma C D, Svoboda M. Expression of the melatonin receptor (MT1) in benign and malignant human bone tumors[J]. J Pineal Res,2007,43(2) :206-213.
  • 5KadekaroAL, Andrade L N, Floeter-Winter L M, et al. MT1 melatonin receptor expression increases the antiproliferative effect of melatonin on S-91 murine melanoma cells[J]. J Pineal Res 2004,36:204-211.
  • 6Collins A, Yuan L, Kiefer T L, et al. Overexpression of the MT1 melatonin receptor in MCF-7 human breast cancer cells inhibits mammary tumor formation in nude mice[J]. Cancer Lett, 2003, 189:49-57.
  • 7Yuan L, Collins A R, Dai J ,et al. MT1 melatonin receptor over expres- sion enhances the growth suppressive effect of melatonin in human breast cancer cells[J]. Mol Cell Endoerinol, 2002,192: 147- 156.
  • 8Hill S M, Cheng C, Yuan L, et al. Declining melatonin levels and MT1 receptor expression in aging rats is associated with enhanced mammary tumor growth and decreased sensitivity to melatonin[J]. Breast Cancer Res Treat,2010.
  • 9Dillon D C, Easley S E, Asch B B, et al. Differential expression of high af- finity melatonin receptors (MT1) in normal and malignant human breast tissue[J]. Am J Clin Pathol,2002,118(3) :451-458.
  • 10靳晓亮,杨波,关方霞,宋来君,李远,焦红亮,郭亚男.肿瘤与肿瘤标志物研究中证据的思考[J].医学与哲学(B),2009,30(2):48-50. 被引量:25

共引文献1

同被引文献27

引证文献2

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部